Connect Biopharma Holdings Ltd shared important news about its asthma treatment, rademikibart, showing good results in a study.

Sep 15, 2026, 7:14 AM ETTrialRead the original at sec.gov

Neutral

Connect Biopharma reported Phase 2 asthma topline results showing a 130 mL FEV1 gain but a missed primary endpoint. Those mixed findings do not change the company's development picture.

CNTB · Connect Biopharma Holdings Ltd

AI read · Neutral

The AI's read

Connect Biopharma announced topline Phase 2 asthma results for rademikibart. The drug showed a 130 mL greater FEV1 improvement (p=0.023) but the trial missed its primary clinical endpoint (p=0.153), so the data are mixed and do not change how we read the program.

Get alerts for CNTB

Follow Connect Biopharma Holdings Ltd (CNTB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CNTB

Free on the App Store and Google Play, or on the web.